Ohm20
Your research and information is invaluable to
Ohm20
Your research and information is invaluable to this community. Thank you!
I have a question for you or others here...
With this huge list, what is the process and potential for trials. I understand that doctors can proscribe off label once approved, but will cytodyn run trials on all these in your opinion. Once revenue starts i would assume there would be enough cash flow to fund and organize numerous trials as well as staff up the corporate office to organize and support. I would assume they would target the largest need or cash flow potential.
What do you see as potential research and uses. I would imagine that without a trial and listing a patient would have to put up a pretty big fight to get LL for their diagnosis when it isnt FDA approved for the application. I would assume it would be the rare doctor to venture off standard protocol.
I ask because i have two family members that have been diagnosed with Alzheimers and Lewy Dementia (which is not on your list and my brief research is not good enough to tunnel down to what makes it tick. Seems to be deposits in brain cells disrupting normal action, but i cant figure out what makes the deposits occur and maybe the researchers dont know either)
Needless to say, I doubt either could be a candidate for LL at this stage of developement and approval. I dont think the Alzheimers study has really started in NY either. Lewy i doubt is on anyones radar.
So given that it seems to me that usage for Alzheimers and most of your other indications is realistically a few years off. I would assume that trials would take at least a year or more per indication depending on the type of disease as well as time for FDA to grant approval.
Am I off base or pretty close to your thoughts?
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
King Risk Partners Grows with New Jersey Acquisition You don't get far in the insurance game without making some bold moves, and King Risk Partners just made a big one—sweeping into New Jersey. They've snagged Conover Beyer Associates Insurance, a firm that's been around longer than some European countries. It's not every day you buy a piece of history, but that's...
Continue Reading
A New Era for Offshore Wind Operations Mark my words, folks, this launch ain't just some minor milestone swaying gently on the industry seas. ZPMC's 'Wind of Ocean' is about to kickstart a whole new game in Europe's offshore wind space. Built with brains and brawn, this vessel embodies the future of sustainable and efficient offshore operations. The announcement from...
Continue Reading
TCL's Forward-Thinking Approach at IFA 2026 IFA 2026 in Berlin got a jolt when TCL Industries and TCL Technology rolled out their ambitious plans under the banner "Inspiration Habitat." By blending cutting-edge smart devices with clean energy advancements, TCL is frantically waving red flags for anyone with an eye on future living trends. The Heartbeat of Inspiration...
Continue Reading
UGREEN Unveils a Cool Revolution in Charging Out in Foxborough, UGREEN is shaking things up at its Smart Living Launch Event. The big reveal? The MagFlow Series, their flagship wireless charging lineup, which promises faster and cooler charging than ever before. UGREEN's taking wireless charging to new heights, and that's got my attention. What Makes MagFlow Stand Out...
Continue Reading
Alright, let's dive into this world of shiny new gadgets that LG Electronics has trotted out at the IFA 2026. As European homes get cozier, folks aren't just after any appliance—they're seeking ones that blend smarts, efficiency, and style. So, LG's rolling out seven of their latest and supposedly greatest home appliances, hoping they'll hit the mark with the modern...
Continue Reading
Public Charity Expands Into Education Well, here's something that's bound to turn a few heads: a fast-growing public charity has just made its first acquisition in the K-12 sphere by snapping up Wayfinder. The stakes are getting interesting. When a charity starts playing in the acquisition space, you're looking at a change in strategy that deserves close attention. Why...
Continue Reading
The Decision to Arm: When Business Risks Demand It You know, deciding whether to hire armed security isn't as clear-cut as some folks make it seem. It ain't just about slapping a guard at your door. There's a whole set of chess moves behind it, especially in good ol' Rochester. When you're juggling high-risk operations, like handling valuable inventory or dealing with...
Continue Reading
Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...
Continue Reading
New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...
Continue Reading
An Acquisition with Enormous Implications Folks, if you haven't been paying attention, you're missing out on a seismic shift. EPC Power's sale to Flex for a hefty $4.4 billion isn't just another transaction; it's a clear signal of where the future's headed, especially if you're plugged into the energy or tech sectors. With the way AI is guzzling power like a thirsty...
Continue Reading
Top 5 Most Recently Viewed Articles
BioCardia Unveils Promising Results in CardiAMP Cell Therapy BioCardia, Inc. (NASDAQ: BCDA), a pioneer in cell therapy for cardiovascular conditions, recently shared the groundbreaking results from its CardiAMP trial. This innovative cellular therapy targets chronic myocardial ischemia, a serious health issue impacting many individuals due to reduced blood flow to the...
Continue Reading
Growth of the Pharmacovigilance Software Market The global pharmacovigilance and drug safety software market is set to experience remarkable growth, projecting an increase of USD 69.1 million over the forecast period running from 2024 to 2028. A key factor influencing this expansion is the rising rates of adverse drug events, which have prompted healthcare and...
Continue Reading
Quaker Houghton Reports Strong Financial Performance for Q3 Quaker Houghton, recognized as a leading provider of industrial process fluids, demonstrated solid performance in its third quarter results. The company's net sales reached an impressive $493.8 million, marking a notable increase of 7% compared to the prior year. This growth was driven by an organic sales volume...
Continue Reading
Nerivio® REN wearable made waves when it gained wider Medicaid coverage back in 2024, opening up significant avenues for migraine treatment across several states like Arizona, New Jersey, Ohio, and Virginia. The buzz was palpable on the trading floor as this initiative could potentially bring affordable migraine relief to seven million more people. You know how these...
Continue Reading
Enhancing Leadership at Augustine Therapeutics Augustine Therapeutics recently announced a significant enhancement to its management team, with the appointments of Virginie Cartage as Chief Financial Officer (CFO) and Dr. Andy Hu as Chief Business Officer (CBO). These strategic additions come at a pivotal moment as the company advances its lead program, AGT-100216, into...
Continue Reading